8-K: Pulse Biosciences Announces First Quarter 2024 Results and Business Updates, Including $60 Million Rights Offering

Pulse Biosciences reported its Q1 2024 financial results, highlighted by FDA clearance for its CellFX nsPFA Percutaneous Electrode and a planned $60 million rights offering.

Summary

• Pulse Biosciences announced its financial and operational results for the first quarter of 2024, ending March 31.
• The company received FDA 510(k) clearance for its CellFX nsPFA Percutaneous Electrode for soft tissue ablation.
• The CellFX nsPFA Cardiac Clamp is still in the 510(k) process, with ongoing discussions with the FDA regarding required clinical data.
• A first-in-human feasibility study for the Cardiac Clamp has been submitted to the Ethics Committee in the Netherlands.
• The company will showcase its CellFX nsPFA 360 Cardiac Catheter at the Heart Rhythm Society meeting with multiple presentations and a live case demonstration.
• Pulse Biosciences plans a rights offering of up to $60 million, with potential additional proceeds of up to $66 million from warrant exercises.
• The rights offering record date has been moved to mid-June.
• Total GAAP costs and expenses for Q1 2024 were $10.6 million, compared to $9.6 million in the same period last year.
• Non-GAAP costs and expenses were $8.6 million, compared to $8.3 million in the prior year period.
• GAAP net loss for the quarter was $10.1 million, compared to $9.8 million in the first quarter of 2023.
• Non-GAAP net loss was $8.1 million, compared to $8.6 million in the same period last year.
• Cash and cash equivalents totaled $34.9 million as of March 31, 2024, down from $54.1 million a year prior.
• Cash used in the first quarter of 2024 was $9.5 million, compared to $7.2 million in the same period last year.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with positive developments like FDA clearance and a planned capital raise, but also negative aspects such as increased losses and a decreasing cash balance. The sentiment is neutral to slightly negative due to the financial concerns.

Positives

• The FDA clearance of the CellFX nsPFA Percutaneous Electrode is a significant milestone.
• The planned rights offering, if fully subscribed, could provide up to $126 million in funding.
• The company is actively advancing its CellFX nsPFA technology for both soft tissue ablation and atrial fibrillation treatment.
• The showcasing of the CellFX nsPFA 360 Cardiac Catheter at the HRS meeting provides valuable exposure.
• The company is engaging in productive dialogue with the FDA regarding the regulatory path for the Cardiac Clamp.

Negatives

• The company experienced an increase in GAAP costs and expenses, primarily driven by non-cash stock-based compensation.
• The company's cash balance has decreased significantly year-over-year.
• The CellFX nsPFA Cardiac Clamp is still in the 510(k) process and requires additional clinical data.
• The company reported a GAAP net loss of $10.1 million for the quarter.

Risks

• The company's ability to successfully complete the rights offering and raise the full $60 million is not guaranteed.
• The CellFX nsPFA Cardiac Clamp requires further clinical data, which could delay its regulatory approval.
• The company's cash burn rate is increasing, which could require additional funding in the future.
• The company's success depends on the market adoption of its CellFX nsPFA technology.

Future Outlook

The company is focused on executing its CellFX nsPFA percutaneous electrode pilot program, advancing clinical and regulatory work for the Surgical Clamp and 360 Cardiac Catheter, and completing the rights offering to fund growth into the first quarter of 2026.

Management Comments

• Kevin Danahy, President and CEO, stated that he is incredibly proud of the team's accomplishments to start the year.
• He also noted that the FDA clearance and the presentations at HRS are early validations of the technology's potential.
• Management is focused on delivering the benefits of CellFX nsPFA to patients and providers following further clinical evaluations and regulatory clearances.

Industry Context

The announcement is relevant to the medical device industry, particularly companies focused on ablation technologies and treatments for atrial fibrillation. The FDA clearance and the planned rights offering position Pulse Biosciences to compete in this space, while the need for further clinical data for the Cardiac Clamp highlights the regulatory hurdles faced by medical device companies.

Comparison to Industry Standards

• The FDA 510(k) clearance for the CellFX nsPFA Percutaneous Electrode is a positive step, comparable to other companies achieving regulatory milestones for similar devices, such as Medtronic's Arctic Front Advance cryoablation system.
• The planned rights offering of up to $60 million is a significant capital raise, similar to other biotech companies seeking funding for clinical trials and commercialization, such as the recent capital raises by companies like AtriCure.
• The company's cash burn rate of $9.5 million in Q1 2024 is relatively high for a company at this stage, and is comparable to other companies in the medical device space with similar R&D expenses, such as Acutus Medical.
• The company's GAAP net loss of $10.1 million is not unusual for a company in the development stage, and is comparable to other companies in the medical device space with similar R&D expenses, such as Biosense Webster.

Stakeholder Impact

• Shareholders will be impacted by the rights offering and the potential dilution of their holdings.
• Employees may be impacted by the company's financial performance and future growth plans.
• Customers and providers may benefit from the company's CellFX nsPFA technology if it is successfully commercialized.
• Creditors may be impacted by the company's financial performance and ability to repay debts.

Next Steps

• The company will execute its CellFX nsPFA percutaneous electrode pilot program.
• The company will continue to advance clinical and regulatory work for the CellFX nsPFA Surgical Clamp and 360 Cardiac Catheter.
• The company will complete the rights offering.
• The company will announce the new record date for the rights offering in mid-June.

Key Dates

Keywords

CellFX nsPFA, Percutaneous Electrode, Cardiac Clamp, Cardiac Catheter, Rights Offering, FDA Clearance, Atrial Fibrillation, Ablation, Financial Results, Medical Device